OptiBiotix Health plc gives world leading Knighton Foods a manufacturing and supply agreement

OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced today it has entered into a manufacturing and supply agreement with Knighton Foods, The agreement grants Knighton an exclusive licence to manufacture and supply OptiBiotix’s SlimBiome(R) weight management technology in the United Kingdom, in return for 50% of the profit, with an agreed cost of manufacture and minimum sales price per kilogramme.

Knighton, a wholly owned subsidiary of Premier Foods plc, is a leading producer of a wide range of high quality, value adding, functional powdered foods, specialist ingredients and finished products, to some of the countries major supermarkets, high street coffee houses, and best-known household brands. Knighton’s advanced powder technology was key to developing an improved version of SlimBiome(R), providing enhanced solubility and better product presentation, greatly improving flavour and mouthfeel.

SlimBiome(R), a patented combination of natural ingredients developed by experts to provide hunger free weight loss, will be supplied by Knighton as a specialised functional ingredient, into a wide range of finished products for use in the retail, vending, and ingredients sectors. Knighton will use their best endeavours to promote and expand the supply of SlimBiome(R), bringing it to the attention of product innovation teams across their wide range of customers.

This agreement, with one of the UK’s leading specialist ingredients suppliers, is an important step in optimising the supply chain by leveraging Knighton’s purchasing power, manufacturing efficiencies and partner network to scale up the manufacture and supply of SlimBiome(R). This is an important step to meet the needs of major UK retailers and exports of SlimBiome(R), and SlimBiome(R) containing products to Tata, and potential new partners, in the Iarge consumer markets of India and the USA.

Stephen O’Hara, CEO of OptiBiotix, commented: “We are pleased to announce the signing of a manufacturing, supply and profit sharing agreement with Knighton Foods. We chose Knighton due to their world leading expertise in adding value and differentiation to speciality powdered ingredients like SlimBiome(R). Their development work greatly improved SlimBiome’s solubility, taste and mouthfeel whilst reducing the overall cost of manufacture. We believe working with Knighton, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and the growing interest we are seeing in SlimBiome(R) from partners worldwide.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really

    Optibiotix Health Plc

    OptiBiotix Health plc will be presenting research at major USA conference

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announced this morning that it will be presenting research data on its microbiome modulators at MicroBiome R&D and Business Collaboration (USA) in San Diego, on 2-3 November 2017. The conference is unique